Welcome to our dedicated page for Nutriband news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. develops prescription transdermal pharmaceutical products and abuse-deterrent patch technology. Company news centers on AVERSA, its transdermal platform that incorporates aversive agents into patches intended to deter abuse, diversion, misuse and accidental exposure for drugs with abuse potential, including opioids and stimulants.
Recurring updates cover the AVERSA Fentanyl program, regulatory and intellectual-property steps, product naming and labeling work, and development relationships tied to transdermal fentanyl. Other company developments include sports tape and kinesiology products, mosquito repellent patches, distribution arrangements, subsidiary matters, shareholder meeting topics, and capital-structure updates affecting Nutriband's Nasdaq-listed common stock and warrants.
Nutriband (NASDAQ:NTRB), a developer of transdermal pharmaceuticals and technology, will host an exclusive live investor webinar on May 30, 2024, at 4:15 p.m. ET.
Organized by RedChip Companies, the event will feature Chairman Serguei Melnik and CEO Gareth Sheridan, who will provide insights into the company's current operations and future milestones.
Investors can register for the free webinar and submit questions beforehand or during the live session.
Nutriband announced the appointment of Sergei Glinka to its board of directors. Glinka, an experienced business leader, brings a wealth of experience from his roles in major European companies. The Glinka family has invested $4.5 million in Nutriband via a private placement in April 2024, which totaled $8.4 million. Nutriband aims to use these funds to complete the FDA approval process for its AVERSA™ technology. AVERSA™, currently patented in 45 countries, is projected to reach peak annual US sales between $80 million and $200 million. The global opioid market was valued at $22.8 billion in 2022.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.